XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.25.2

Royalty Monetization Arrangement | 6 Months Ended
--- | ---
Jun. 30, 2025
Liability related to future royalties [Abstract] |
Royalty Monetization Arrangement | Royalty Monetization Arrangement In June 2025, the Company and Sagard Healthcare Partners (Sagard) entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) pursuant to which the Company sold to Sagard its right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) occurring on and after July 1, 2025 under the Company’s Global Collaboration and License Agreement, dated as of October 24, 2017, as amended (Incyte License Agreement), with Incyte Corporation (Incyte). Under the terms of the Royalty Purchase Agreement, the Company received a cash payment of $70.0 million. In exchange, Sagard acquired the royalties payable to the Company under the License Agreement for global net sales of ZYNYZ, subject to a cap. Following Sagard’s receipt of aggregate royalty payments totaling $140.0 million, the Company will resume collecting all future royalties under the License Agreement. The Company has retained its other economic interests related to ZYNYZ, including future potential development, regulatory and commercial milestones. The $70.0 million proceeds received from Sagard under the Royalty Purchase Agreement were recorded as a liability related to future royalties, net of transaction costs of $0.3 million, which will be amortized over the estimated life of the arrangement using the effective interest rate method. The Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company has significant continuing involvement in the generation of cash flows due to Sagard and other existing obligations under the License Agreement. Royalty revenue will be recognized as earned on net sales of ZYNYZ, and the Company will record the royalty payments Incyte makes to Sagard as a reduction of the liability when paid. The aggregate future estimated payments, less the $69.7 million of net proceeds, will be recorded as interest expense over the estimated life of the arrangement. As such payments are made to Sagard, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement. The Company estimates the payments to be made to Sagard over the term of the Royalty Purchase Agreement based on forecasted royalties and will calculate the effective interest rate required to discount such payments back to the liability balance. As of June 30, 2025, the estimated effective interest rate under the agreement was approximately 14.6%. Over the course of the Royalty Purchase Agreement, the actual effective interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as necessary. The company recognized non-cash interest expense of $0.6 million during the three months ended June 30, 2025, which is reflected in the interest and other expense line on the consolidated statements of operations. Changes to the liability related to future royalties were as follows for the six months ended June 30, 2025 (in thousands):
Liability related to future royalties - beginning balance | $ | — |  |
Proceeds from sale of future royalties | 70,000 |  |
Deferred transaction costs | (327) |  |
Non-cash interest expense recognized | 587 |
Liability related to future royalties - ending balance | $ | 70,260 |  |

X
- Definition Liability related to future royalties [Abstract] + References No definition available. + Details
Name: | mgnx_LiabilityRelatedToFutureRoyaltiesAbstract
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability Related To Sale Of Future Royalties + References No definition available. + Details
Name: | mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock
Namespace Prefix: | mgnx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration